Caliway started phase 3: analyst targets Caliway Biopharmaceuticals C stock at TWD 240.00
Published on 10/13/2026 at 10:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS- Caliway started the 320-participant SUPREME-01 phase 3 trial on September 23, 2026.
- One analyst target stands at TWD 240.00, according to Investing.com on October 8, 2026.
- Q2 2026 revenue was TWD 3.57 million and net loss was TWD 222.52 million.
- Caliway stock was last quoted at TWD 76.50 on the Taiwan Stock Exchange on October 13, 2026.
Caliway Biopharmaceuticals C (ISIN TW0006919004) had started the global SUPREME-01 phase 3 trial for CBL-514 on September 23, 2026. According to Caliway, the study is designed to enroll 320 participants, while Investing.com listed one analyst target of TWD 240.00 on October 8, 2026.
Three milestones, one pipeline
On September 21, 2026, Caliway reported that its CBL-0202DD phase 2 study achieved its primary endpoint in Dercum disease.
On September 23, 2026, the first participant received treatment in SUPREME-01, a phase 3 study for large-area abdominal fat reduction, with 320 planned participants. On October 2, 2026, Caliway published phase 2 data showing that 69.60 percent of treated participants achieved at least 150 mL of subcutaneous fat reduction at the eight-week follow-up, compared with 0 percent for placebo, according to Caliway.
What does phase 3 change?
The 320-person design shifts the story from early efficacy evidence toward a larger controlled test. The company is evaluating patient and clinician abdominal-fat rating scales alongside MRI-based assessments, giving the program three distinct measurement angles.
The October data also included visceral-fat results. In the subgroup with MRI follow-up, visceral fat fell 12.01 percent from baseline after four weeks of treatment, while the placebo group rose 5.68 percent, a 17.69 percentage-point difference reported in the company release.
Revenue remains an early-stage metric
Investing.com reported Q2 2026 revenue of TWD 3.57 million, net loss of TWD 222.52 million and earnings per share of minus TWD 0.14. The financial profile remains dominated by research spending while CBL-514 advances through clinical development.
Next reporting date is November 11
Investing.com lists November 11, 2026 as the next reporting date. The timing places the next financial update after the company presents additional clinical development progress from its phase 3 program.
Stock stays near its yearly low
Caliway was last quoted at TWD 76.50 on the Taiwan Stock Exchange on October 13, 2026 at 1:30 p.m. TST. Its finance-market range for the preceding 52 weeks was TWD 75.10 to TWD 188.00, while market capitalization stood at TWD 119.1 billion.
Caliway Biopharmaceuticals C stock facts
- Company: Caliway Biopharmaceuticals Co., Ltd.
- ISIN: TW0006919004
- Ticker: 6919
- Primary exchange: Taiwan Stock Exchange
- Price on Taiwan Stock Exchange (as of October 13, 2026, 1:30 p.m. TST): TWD 76.50
- Market capitalization: TWD 119.1 billion (as of October 13, 2026)
- 52-week range: TWD 75.10-188.00 (as of October 13, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 11, 2026
Market context: Market report TAIEX.
More news and analyses on Caliway Biopharmaceuticals C stock
